Netramark Holdings Inc. Stock
€0.72
Your prediction
Financial data and news for Netramark Holdings
sharewise wants to provide you with the best news and tools for Netramark Holdings, so we directly link to the best financial data sources.
Financials
News
NetraMark Delivers Transformational Quarter of Execution
Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award Secured
TORONTO, ON, December 18, 2025 –
NetraMark Achieves Major FDA Milestone
TORONTO, ON, December 15, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is
NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio
TORONTO, ON, December 8, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is
NetraMark Signs Four New Contracts with a Leading Global Pharmaceutical Company to Enhance Clinical Trial Insights
TORONTO, ON, November 18, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company
NetraMark Signs Contract with a Leading Global Biopharmaceutical Company to Enhance Clinical Trial Insights
TORONTO, ON, November 3, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is
NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research
TORONTO, ON, September 22, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is
Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study
TORONTO, ON, AUGUST 5, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming
NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity
TORONTO, ON, JULY 30, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming
NetraMark Signs Contract With Algo Tx to Enhance Clinical Trial Design for ATX01
TORONTO, ON, JULY 28, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming
Netramark’s AI Significantly Outperforms ChatGPT, Deepseek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success
TORONTO, ON, JUNE 23, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is